

Parplom ET Injection

Caffeine I.P. 100mg + Ergotamine Tartrate I.P. 1mg + Paracetamol I.P. 250mg + Prochlorperazine Maleate I.P. 2.5mg Injection

This combination injection is designed for the management of acute migraine attacks and associated symptoms. It combines the vasoconstrictive properties of ergotamine, the analgesic effects of paracetamol, the anti-nausea properties of prochlorperazine, and the stimulant effect of caffeine for comprehensive relief from migraine symptoms.

Composition (per ml):

- **Caffeine I.P. 100mg:** A central nervous system stimulant that enhances the effectiveness of ergotamine and alleviates fatigue.
- **Ergotamine Tartrate I.P. 1mg:** A vasoconstrictor that reduces the dilation of blood vessels in the brain, a primary cause of migraines.
- **Paracetamol I.P. 250mg:** An analgesic and antipyretic agent for pain relief and fever reduction.
- **Prochlorperazine Maleate I.P. 2.5mg:** An antiemetic that alleviates nausea and vomiting often associated with migraines.

Uses:

1. **Acute Migraine Management:**
 - Provides quick relief from severe migraine headaches and associated symptoms like nausea and vomiting.
2. **Cluster Headaches:**

- Effective in managing episodic cluster headaches.

3. **Tension Headaches:**

- Helps alleviate tension-type headaches when other treatments are inadequate.

Mechanism of Action:

- **Ergotamine:** Acts on serotonin (5-HT) receptors to constrict dilated blood vessels in the brain, reducing headache intensity.
- **Caffeine:** Enhances the absorption and effectiveness of ergotamine, improving its action.
- **Paracetamol:** Reduces pain by inhibiting prostaglandin synthesis in the central nervous system.
- **Prochlorperazine:** Blocks dopamine receptors to reduce nausea and vomiting, enhancing patient comfort.

Dosage & Administration:

- **Adults:** 1 injection (dose as prescribed) administered intramuscularly (IM) or intravenously (IV) by a healthcare professional.
- **Maximum Dose:** Do not exceed the prescribed dose as frequent use may cause medication overuse headaches or ergotism.
- **Route:** Administered only under medical supervision.

Contraindications:

- **Hypersensitivity to any component of the injection.**
 - **Cardiovascular Disease: Avoid use in patients with coronary artery disease, hypertension, or peripheral vascular disease.**
 - **Pregnancy and Lactation: Contraindicated during pregnancy due to the risk of uterine contraction and reduced blood flow to the fetus.**
 - **Severe Liver or Kidney Impairment.**
 - **Ergotism or Vasospastic Conditions.**
-

Side Effects:

- **Common:**
 - **Nausea, dizziness, or mild gastrointestinal discomfort.**
 - **Injection site reactions (redness, pain, or swelling).**
 - **Serious (Rare):**
 - **Ergotism (severe vasospasm leading to numbness or gangrene).**
 - **Cardiac arrhythmias or chest pain.**
 - **Hypertension or bradycardia.**
-

Precautions:

- 1. Monitor for Ergotism: Avoid overuse as ergotamine can cause severe vasospasm.**
 - 2. Avoid Use with Certain Drugs: Do not combine with other vasoconstrictors, triptans, or strong CYP3A4 inhibitors (e.g., ketoconazole).**
 - 3. Caution in Elderly: Increased risk of cardiovascular side effects.**
 - 4. Alcohol and Smoking: Avoid during treatment as they may exacerbate side effects.**
-

Drug Interactions:

- **Triptans or Other Vasoconstrictors: Increased risk of severe vasospasm.**
 - **CYP3A4 Inhibitors (e.g., macrolides): May increase ergotamine levels and toxicity.**
 - **Antihypertensives: Caution as ergotamine may antagonize their effects.**
-

Storage:

- **Store below 25°C, away from direct sunlight and moisture.**
 - **Keep out of reach of children.**
-

Note: This injection is intended for acute migraine episodes and should not be used for regular prophylaxis or chronic headache management. It must be administered only under the supervision of a qualified healthcare provider. Discontinue use and seek immediate medical attention if serious side effects occur.

Manufactured in India for:

CafoliTM
L I F E C A R E

Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for